Zacks: Brokerages Expect Neurocrine Biosciences, Inc. (NBIX) Will Announce Quarterly Sales of $136.12 Million

Wall Street brokerages expect Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to report sales of $136.12 million for the current quarter, Zacks reports. Eight analysts have made estimates for Neurocrine Biosciences’ earnings, with the highest sales estimate coming in at $142.00 million and the lowest estimate coming in at $127.10 million. Neurocrine Biosciences reported sales of $71.09 million in the same quarter last year, which indicates a positive year over year growth rate of 91.5%. The company is scheduled to announce its next earnings results on Monday, April 29th.

According to Zacks, analysts expect that Neurocrine Biosciences will report full-year sales of $671.48 million for the current fiscal year, with estimates ranging from $630.61 million to $733.66 million. For the next fiscal year, analysts expect that the company will report sales of $967.52 million, with estimates ranging from $903.00 million to $1.02 billion. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Neurocrine Biosciences.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Tuesday, February 5th. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.05. Neurocrine Biosciences had a return on equity of 5.06% and a net margin of 4.68%. The business had revenue of $131.49 million during the quarter, compared to the consensus estimate of $132.32 million. During the same quarter last year, the company earned $0.07 earnings per share. The company’s quarterly revenue was up 39.1% on a year-over-year basis.

A number of analysts have recently commented on NBIX shares. ValuEngine upgraded Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research report on Tuesday. BidaskClub upgraded Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research report on Thursday, March 14th. Oppenheimer boosted their price target on Neurocrine Biosciences from $105.00 to $110.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 13th. Zacks Investment Research cut Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research report on Saturday, February 9th. Finally, Bank of America dropped their price target on Neurocrine Biosciences from $124.00 to $117.00 and set a “buy” rating for the company in a research report on Wednesday, February 6th. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $102.56.

Shares of Neurocrine Biosciences stock traded down $2.79 on Wednesday, reaching $84.83. 558,912 shares of the stock were exchanged, compared to its average volume of 977,201. The company has a quick ratio of 8.24, a current ratio of 8.36 and a debt-to-equity ratio of 0.81. Neurocrine Biosciences has a twelve month low of $64.72 and a twelve month high of $126.98. The company has a market capitalization of $7.96 billion, a price-to-earnings ratio of 385.59, a price-to-earnings-growth ratio of 27.34 and a beta of 1.86.

In related news, insider Kyle Gano sold 3,809 shares of the business’s stock in a transaction that occurred on Tuesday, February 5th. The stock was sold at an average price of $88.12, for a total transaction of $335,649.08. Following the completion of the sale, the insider now directly owns 17,595 shares in the company, valued at $1,550,471.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eiry Roberts sold 1,857 shares of the business’s stock in a transaction on Tuesday, January 8th. The stock was sold at an average price of $84.09, for a total value of $156,155.13. Following the transaction, the insider now directly owns 3,143 shares in the company, valued at approximately $264,294.87. The disclosure for this sale can be found here. Insiders have sold 13,280 shares of company stock valued at $1,163,054 over the last quarter. 4.30% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Acadian Asset Management LLC acquired a new position in Neurocrine Biosciences during the fourth quarter worth $32,000. Exane Derivatives boosted its stake in Neurocrine Biosciences by 48,400.0% during the fourth quarter. Exane Derivatives now owns 485 shares of the company’s stock worth $35,000 after buying an additional 484 shares during the last quarter. Rehmann Capital Advisory Group boosted its stake in Neurocrine Biosciences by 54.7% during the third quarter. Rehmann Capital Advisory Group now owns 557 shares of the company’s stock worth $68,000 after buying an additional 197 shares during the last quarter. Penserra Capital Management LLC acquired a new position in Neurocrine Biosciences during the fourth quarter worth $86,000. Finally, Arbor Wealth Management LLC acquired a new position in Neurocrine Biosciences during the fourth quarter worth $92,000. 99.82% of the stock is currently owned by institutional investors.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.

Recommended Story: Understanding Price to Earnings Ratio (PE)

Get a free copy of the Zacks research report on Neurocrine Biosciences (NBIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.